NCE-1 Intelligence & Market Opportunity

Velsipity

Etrasimod

Antiulcer

Tablet

Velsipity is a once-daily pill for adults with moderately to severely active ulcerative colitis. It modulates S1P receptors to reduce inflammation and maintain remission.

Approval Date

12-Oct-23

NCE-1 Date

12-Oct-27

NCE Date

12-Oct-28

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

345

2027

515

2028

699

2029

764

2030

732

2031

744

2032

767

Molecule profile

Details & specifications

Molecule

Etrasimod

Innovator

PFIZER INC

Dosage Form

Tablet

Strength

2 mg base

Therapeutic Category

Antiulcer

Usage

To treat moderately to severely active ulcerative colitis in adults

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.